There was no doubt that hauling Martin Shkreli, the infamous young pharmaceutical entrepreneur, in front of Congress would be dramatic. Of course it was. But did it get us any closer to preventing the next Martin Shkreli from taking an old drug and raising the price 5,000%?
Read Full Article »
